Wolverine Peptide — Passes The Safety Check

High-Dose IV BPC-157 Safety Pilot Study: Zero Side Effects at 20–40× Typical Biohacking Levels (New 2025 Data)

If you’ve been following the peptide scene, BPC-157 has been one of the most talked-about compounds for tissue repair, gut health, and recovery. But one persistent knock has always been the lack of solid human safety data—especially at the kinds of doses people actually experiment with.

A brand-new pilot study just changed that. Published in 2025, it tested intravenous BPC-157 at doses that make standard biohacking protocols look tiny. And the results? Clean. No side effects, no lab abnormalities. Here’s exactly what happened, why it matters, and why you should still approach it with eyes wide open.

Quick Background on BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide modeled after a protective protein found in human gastric juice. Animal research (hundreds of studies) has shown impressive effects on tendon healing, muscle repair, gut lining integrity, and even neuroprotection. Typical “biohacking” protocols use 200–500 mcg per day via subcutaneous injection—sometimes split into two doses.

What’s been missing? Large-scale human trials. Until now, almost everything was extrapolated from rodents or anecdotal reports. That changed with this pilot.

The 2025 IV Safety Pilot Study (Lee & Burgess)

Study Design

• Participants: 2 healthy adults (small pilot—explicitly labeled as such)
• Route: Intravenous infusion (not subQ)
• Dosing schedule:
  • Day 1: 10 mg BPC-157 diluted in 250 mL normal saline, infused over 1 hour
  • Day 2: 20 mg BPC-157 in the same 250 mL saline, infused over 1 hour

That’s 20–40× a standard daily biohacking dose, and the equivalent of multiple full research vials in a single session. For context, many commercial BPC-157 vials are 5–10 mg each.

Measurements

• Comprehensive blood panels: cardiac, liver, kidney, thyroid, fasting glucose, etc.
• Vital signs before, during, and after each infusion
• Subjective side-effect reporting

Results

• Zero reported side effects in either participant
• No changes in heart, liver, kidney, thyroid, or glucose markers
• Plasma levels returned to baseline within 24 hours—suggesting rapid clearance

Full citation: Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025;31(5):20-24. PMID: 40131143.

Why This Is a Big Deal for the Biohacking Community

• IV route is the harshest test: Clearing this safety hurdle at high doses is reassuring
• Dose escalation was aggressive: Straight to 10 mg then 20 mg with no lower-dose ramp and still no issues
• First peer-reviewed human IV data: Most prior mentions were anecdotal or non-published

Important Limitations

• n=2 pilot—cannot prove long-term safety
• Not tested in people with medical conditions or on medications
• Does not confirm efficacy—purely safety-focused
• BPC-157 remains not FDA-approved for human use

Bottom Line

This 2025 pilot study is the strongest human safety signal yet for BPC-157 at doses far beyond typical biohacker use. No lab derangements, no side effects, even via IV. Still, “promising pilot” is not the same as “proven safe forever.”

Treat experimental compounds cautiously: source pharmaceutical-grade material, track labs, start low, and work with a clinician.

Not medical advice. For informational purposes only. Always consult your physician before using any research peptide.